Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Rite Aid

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24%.

Should You Buy Bio-Rad Laboratories Stock After Its 50% Fall This Year?

QIAGEN

A rumored matchup between Bio-Rad Laboratories and Qiagen is unlikely, an analyst said Tuesday as BIO stock fell for a second straight day. The post Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely appeared first on Investor's Business Daily.

Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely

Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market

California-based diagnostics company Bio-Rad Laboratories is in talks to merge with Qiagen NV , the Wall Street Journal reported on Monday, citing people familiar with the matter.

Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ

Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

Bio-Rad Laboratories in Talks to Combine With Qiagen

Align Technology

Advanced Micro Devices

Caesars Entertainment

DISH Network

Generac Holdings

MGM Resorts

News Corp

Bio-Techne

Warner Bros Discovery Inc

Analysts are either optimistic or delusional. But either way, they see a big S&P 500 29% rally coming — and have picked favorite stocks.

10 Stocks Are Screaming Buys As Monster Rally Nears, Analysts Say

Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

Haemonetics

Lantheus Holdings

Zimmer Biomet Hlds

Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.

4 Stocks to Watch Amid Recovering Medical Products Industry

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland, based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 mi

Bio-Rad Acquires Curiosity Diagnostics

Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2022 Earnings Conference Call July 28, 2022 6:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President of Life Science Group Dara Wright - President of Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Good afternoon. Thank you for attending today's Bio-Rad Second Quarter 2022 Earnings Results Conference Call.

Bio-Rad Laboratories, Inc. (BIO) Management on Q2 2022 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compared to $715.9 million reported for the second quarter of 2021. COVID-related revenue was approximately $33 million in the second quarter of 2022 versus approximately $69 million re

Bio-Rad Reports Second-Quarter 2022 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2022 on Thursday, July 28, 2022, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day. To participate, call 844-200-6205 within the U.S. or +1 929-526-1599 outside the U.S., acc

Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its inaugural corporate sustainability report. The report is based on an assessment Bio-Rad conducted in 2021 to identify the highest priority topics for sustainability and to set targets for improvement. It is prepared in accordance with Global Reporting Initiative (GRI) Standards: Core Option. Bio-Rad's top sustainability

Bio-Rad Publishes Corporate Sustainability Report

Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.

Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid

The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade

Lamb Weston Hlds

Moderna

Match Group

Prologis

Molson Coors Brewing

T-Mobile US

Twitter

Vornado Realty Trust

It's always tough to predict which S&P 500 companies will beat earnings forecasts. But analysts still think you can profit from some that did.

9 Stocks That Crushed Estimates Are Still Undervalued, Analysts

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2022 Earnings Conference Call April 28, 2022 6:00 PM ET Company Participants Ed Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President of Life Science Group Norman Schwartz - Chief Executive Officer Dara Wright - President of Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Brandon Couillard - Jefferies Jack Meehan - Nephron Research Operator Good afternoon. Thank you for attending today's Bio-Rad Laboratories Q1 2022 Financial Results Call.

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2022 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2022. First-quarter 2022 net sales were $700.1 million, a decrease of 3.7 percent compared to $726.8 million reported for the first quarter of 2021. On a currency-neutral basis, quarterly sales decreased 0.8 percent compared to the same period in 2021. COVID-related r

Bio-Rad Reports First-Quarter 2022 Financial Results

Labcorp Holdings Inc

ResMed

Thermo Fisher Scientific

Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.

Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More

Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2022 on Thursday, April 28, 2022, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day. To listen, call 844-200-6205 within the U.S. or 929-526-1599 outside the U.S., access code: 49326

News for Bio-Rad Laboratories Stock (BIO)